21 Jun 2010: NIH-supported study finds novel pathway May open doors for new blood pressure treatments
Researchers have found that increasing certain proteins in the blood vessels of mice, relaxed the vessels, lowering the animal’s blood pressure. The study provides new avenues for research that may lead to new treatments for hypertension.
'The paper demonstrates that cytochrome P450 plays an important role in the management of high blood pressure, a disease of enormous public health concern,' said Darryl Zeldin, M.D., acting clinical director of the National Institute of Environmental Health Sciences (NIEHS) and senior author on the paper.
According to the Centers for Disease Control and Prevention, about 1 in 3 adults in the United States has high blood pressure, which increases the risk for heart disease and stroke, the first and third leading causes of death in the United States.
The study, published online in The FASEB Journal, was conducted by researchers at NIEHS who teamed with investigators at the University of North Carolina at Chapel Hill (UNC), Medical College of Wisconsin, Milwaukee, and Oregon Health and Science University, Portland.
The researchers created animal models that had a human cytochrome P450 (CYP450 or P450) in the cells that line their blood vessels. The mice with the P450 generated more substances called epoxyeicosatrienoic acids or EETs, known for their role in protecting the cardiovascular system. EETs relax and dilate the blood vessels and fight inflammation.
'We found that when the animals were exposed to substances known to increase blood pressure, the animals with the P450 had lower blood pressure and less damage to the kidneys compared to normal mice,' said Craig R. Lee, Pharm.D., Ph.D., assistant professor at UNC and lead author on the paper. 'We hope that these studies will advance the development of new treatments for high blood pressure.'
'This is a great example of a basic finding that improves our understanding of a metabolic pathway that can be used to develop improved treatments for those suffering from a common disease like hypertension,' said Linda Birnbaum, Ph.D., director of the NIEHS and the National Toxicology Program.
Related news
-
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced the publication of preclinical data in the peer-reviewed journal Cancer Immunology, Immunotherapy, for its lead clinical oncology program, RTX-240, for the treatment of adults with advanced solid tumors and relapsed/refractory acute myeloid leukemia. The paper entitled “Ant...
-
Part of the Cell and Gene Therapy Catapult PAT Consortium
Imspex is delighted to be part of the ground-breaking process analytical technologies (PAT) consortium announced today by the Cell and Gene Therapy Catapult. The consortium of over 20 pharmaceutical companies, technology providers, therapy developers and charities is the largest in the cell and gene therapy space to date with a mission to co-create industry-specific solutions that improve monitoring and control during the manufacturing process of cell and gene therapy materials. We are looking forward to playing...
-
Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. EDT. A live audio webcast will be available within the Investors & Media section of the...
-
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the Company will present a Trials in Progress poster presentation for its lead artificial antigen-presenting (aAPC) cell program, RTX-321, at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually from June 4-8, 2021. The Trials in Progress...
-
Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society
Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval of the first CAR T cell immunotherapy for multiple myeloma developed by Bristol Myers Squibb and bluebird bio. Abecma® (idecabtagene vicleucel; ide-cel) is a chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of certain adult patients with relapsed or refractory multiple myeloma, a blood cancer formed by malignant plasma cells and...
Customer comments
No comments were found for 21 Jun 2010: NIH-supported study finds novel pathway May open doors for new blood pressure treatments. Be the first to comment!